Aromatase inhibitors for breast cancer: Pharmacoeconomic considerations

Expert Opinion on Pharmacotherapy

Volumn 2, Issue 6, 2001, Pages 987-995

  Higa, G M ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

Adjuvant therapy; Anti oestrogen; Aromatase; Aromatase inhibitor; Hormone dependent breast cancer; Neo adjuvant therapy; Oestrogen receptor; Oestrogens; Palliative therapy; Preventive therapy

Indexed keywords

ANASTROZOLE; ANTIESTROGEN; AROMATASE; AROMATASE INHIBITOR; ESTROGEN; ESTROGEN RECEPTOR; EXEMESTANE; FADROZOLE; FORMESTANE; LETROZOLE; MEGESTROL ACETATE; TAMOXIFEN; VOROZOLE;

ADULT; ADVANCED CANCER; AGED; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG POTENCY; DRUG TOLERABILITY; FEMALE; HORMONE DEPENDENCE; HUMAN; HUMAN TISSUE; OVARIECTOMY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; PREMENOPAUSE; QUALITY OF LIFE; REVIEW; SIDE EFFECT;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; ECONOMICS, PHARMACEUTICAL; ENZYME INHIBITORS; ESTROGEN ANTAGONISTS; FEMALE; GUIDELINES; HUMANS; POSTMENOPAUSE; PREMENOPAUSE; RECEPTORS, ESTROGEN; TAMOXIFEN;

EID: 0034875860     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2.6.987     Document Type: Review

References (47)

1. Cancer statistics, 2000
2. Cancer of the breast. The past decade
3. Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer
4. Utilization of oxygen and reduced nicotinamide adenine dinucleotide phosphate by human placental microsomes during aromatization of androstenedione
5. Source of estrogen production in postmenopausal women
6. DNA-based variation at the aromatase gene (CYP19) and its role in breast cancer susceptibility
7. Enzymatic control of estrogen production in human breast cancer: Relative significance of aromatase versus sulphatase pathways
8. Exemestane improves survival compared with megoestrol acetate in postmenopausal patients with advanced breast cancer who have failed on tamoxifen: Results of a double-blind randomized Phase III trial
9. A multicentre, randomized, pharmacokinetic, endocrine and clinical study to evaluate formestane in breast cancer patients at first relapse: Endocrine and clinical results
10. Fadrozole HCI (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: Results of two randomized double blind controlled multi-institutional trials
11. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer
12. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate
13. Randomized Phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients
14. Is health economics useful in cancer?
15. Predicting the future health care expenses of cancer
16. Integrating economic analysis into cancer clinical trials: The National Cancer Institute
17. Evaluation of conflict of interest in economic analyses of new drugs used in oncology
18. Steroid receptors in human breast cancer
19. Long-term follow-up of elderly patients with locoregional breast cancer treated with tamoxifen only
20. An evaluation of early or delayed adjuvant chemotherapy in premenopausal patients with advanced breast cancer undergoing oophorectomy: A later analysis
21. Combination chemotherapy compared to tamoxifen as initial therapy for stage II breast cancer in elderly women
22. Clinical Oncological Society of Australia. A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination
23. Endocrine therapy of metastatic breast cancer
24. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial
25. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the tamoxifen or arimidex randomized group efficacy and tolerability study
26. Regulation of aromatase expression in human tissues
27. Resistance of the ovary to blockade of aromatization with aminoglutethimide
28. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: Results of a survival update based on a combined analysis of data from two mature Phase III trials
29. Anastrozole cost effective in advanced breast cancer
30. Cost-effectiveness analysis of exemestane compared with megestrol acetate in patients with advanced breast carcinoma
31. Chemotherapy is antihormonal therapy-how much proof do oncologists need?
32. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation
33. Ten year results from the NSABP clinical trial evaluating the use of 1-phenylalanine mustard (L-PAM) in the management of primary breast cancer
34. Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer
35. A randomized trial of adjuvant combination chemotherapy with or without prednisone in premenopausal breast cancer patients with metastases in one to three axillary lymph nodes
36. Ovarian ablation in early breast cancer: An overview of randomized trials
37. Tamoxifen for early breast cancer: An overview of the randomized trials
38. Arimidex, tamoxifen alone or in combination (ATAC) adjuvant trial in post-menopausal breast cancer
39. The value of mammography screening in women under age 50 years
40. Ten-to-fourteen-year effect of screening on breast cancer mortality
41. Indications for neoadjuvant chemotherapy for breast cancer
42. Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer
43. The expression of Ki-S1 and BCL-2 and the response to primary tamoxifen therapy in elderly patients with breast cancer
44. Molecular origin of cancer: Catechol estrogen-3,4-quinones as endogenous tumor initiators
45. An association between the allele coding for a low activity variant of catechol-O-methyltransferase and the risk for breast cancer
46. Biomarkers in early breast neoplasia
47. Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA induced rat mammary carcinomata